The jointly funded project positions GE HealthCare to develop ultrasound technologies that non-expert users can operate.
The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...
GE HealthCare today announced a $35 million collaboration with the Biomedical Advanced Research and Development Authority ...
TCMD Q4 2025 earnings call recap: revenue, margin expansion, LymphaTech acquisition, and 2026 guidance amid Medicare prior authorization risk—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results